It is suggested that NT pathway-specific polygenic profiling may capture clinically relevant variation overlooked by genome-wide approaches in SCZ by identifying genetic profiles associated with symptom severity, disease onset, and longitudinal outcomes.
Abstract
Schizophrenia (SCZ) is a highly heritable psychiatric disorder characterised by substantial clinical heterogeneity. While global polygenic scores (gPGS) capture genetic liability to SCZ, their ability to explain clinical variability remains limited. Pathway-stratified polygenic scores (sPGS) offer a biologically informed approach to patient stratification. In this study, common genetic variants were annotated across five neurotransmitter (NT) signalling pathways - acetylcholine (ACh), dopamine, gamma-aminobutyric acid (GABA), glutamate (Glu), and serotonin. sPGS adjusted for sex and ancestry principal components, were calculated in two independent cohorts with different available clinical data (N=3,044 and N=645). By clustering top-decile individuals across the five sPGS dimensions, we classified patients into five mutually exclusive patient profiles, which were then evaluated for their associations with Positive and Negative Syndrome Scale (PANSS) symptom dimensions, age at disease onset (AAO), and three-year clinical remission and treatment response. Although gPGS showed no significant association with clinical outcomes, some sPGS-derived profiles captured clinically relevant heterogeneity across cohorts. Patients assigned to the Ach profile exhibited higher overall symptom severity, particularly negative symptoms and general psychopathology. Patients within the Glu profile were characterised by more severe negative symptoms, earlier AAO, reduced three-year remission, and poorer treatment response. Similarly, the GABA risk profile was also associated with three-year remission rates. These findings suggest that NT pathway-specific polygenic profiling may capture clinically relevant variation overlooked by genome-wide approaches. By identifying genetic profiles associated with symptom severity, disease onset, and longitudinal outcomes, this framework could contribute to biologically informed patient stratification and inform future precision psychiatry approaches in SCZ.
Polygenic scores (PGS) for schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BD) are used to explain heterogeneity in schizophrenia, but European-derived scores applied in ancestrally mixed samples risk confounding by population structure. In the CATIE trial, we tested 3 a priori directional h...
A. Serretti· American Journal of Medical...· 0 citations
Biologically informed polygenic scores (PGSs) may help interpret genetic associations with treatment outcomes. Here, we computed neurotransmitter-based PGSs (NeuroPGSs) for patients with major depressive disorder (MDD) and assessed their association with SSRI treatment outcomes. By targeting genetic variants involved i...
N. Sharew, S. Clark, V. Arolt et al.· medRxiv· 0 citations
BACKGROUND
The psychosis continuum conceptualises psychotic phenomena as existing on a spectrum from subclinical experiences to psychotic disorders. Despite epidemiological and clinical evidence in support of this model, few studies have examined polygenic liability across the severity continuum: from subclinical exper...
S. Haussler, D. Prata, M. Kempton et al.· The British journal of psych...· 0 citations
Polygenic scores for major depression, schizophrenia and bipolar disorder have been related to treatment outcome. We analysed 4,007 patients of European ancestry from 7 cohorts: three with major depression (STAR*D, GSRD, PANDORA), two with bipolar disorder (STEP-BD, Barcelona) and two with schizophrenia (CATIE, HSRRm)....
A. Serretti, D. Souery, S. Kasper et al.· medRxiv· 0 citations
Analysis of polygenic risk scores in the UK Biobank reveals both shared and disease-specific genetic contributions across neurodegenerative disorders and demonstrates that currently available cell-type specific gene sets capture substantial overlapping genetic risk.
E. Simmonds, A. McKeever, U. Yaman et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.